Navigation Links
GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
Date:10/17/2007

SPOKANE, Wash., Oct. 17 /PRNewswire/ -- GenPrime, Inc. a leading provider of rapid microbial analysis technologies, has initiated multi-site clinical trials of its Bacterial Contamination Test for Platelets(TM). The test is a rapid QC device for detecting the presence of aerobic and anaerobic bacteria commonly found in contaminated platelets. The trial will generate data for filing a 510 (K) pre-market notification with the Food and Drug Administration (FDA).

"Undetected bacterial contaminants in platelets tested by culture, dipsticks and other current methods remain a significant source of sepsis and associated patient mortality and morbidity in transfusion medicine," said Buck Somes, chief executive officer of GenPrime. "We believe our technology will offer a practical and rapid solution to further mitigate this problem."

Currently, over 10 million platelet units are transfused annually into patients worldwide. It is estimated by transfusion medicine experts that as many as 1 in 2000 of these units are contaminated with bacteria. While culture based tests, which can take two to three days before results are available, have reduced the chances of contaminated platelets being infused, septic reactions continue to be reported. Traditional rapid tests such as dipsticks, staining and microscopy are highly unreliable. There remains an unmet need in the transfusion industry for a sensitive, rapid, and reliable test that is user friendly and can provide accurate, objective results.

Based on a novel, easy to use, proprietary lateral flow technology platform, GenPrime's Bacterial Contamination Test for Platelets(TM) is designed to detect all 15 organisms known to contaminate platelets. Additionally GenPrime has developed an automated test reader and software for objective result analysis and data collection. The company has completed optimization, scale-up and pre-clinical studies of the test and expects to complete the clinical trial and file the 510(K) pre-market submission to the FDA in early 2008.

For additional information, contact GenPrime, Inc., 157 South Howard, Suite 605 Spokane, WA 99201 USA, Toll Free: 1.866.624.9855, Ph: 509.624.9855, info@genprime.com

About GenPrime, Inc.

GenPrime is committed to becoming the leading provider of innovative technologies for a secure and healthy world. It currently provides products to the homeland security, and fermentation sciences industries. The Company is currently gearing up for its largest product launch yet, a highly sought after bacterial test for blood products in the healthcare and transfusion services industries. http://www.genprime.com


'/>"/>
SOURCE GenPrime, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
6. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
7. Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
8. The Power of External Influence on Our Lives
9. Demonstrations by staff in medical college against violence by external agencies
10. External Catheters Linked with decreased UTI Risk in Men
11. Corneal infections Linked to External Contamination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... ... Silverado today is pleased to announce that it has entered into a management ... Alexandria, Virginia. The new community is expected to open its doors in the first ... three-story community with underground parking – located on King Street –will serve 66 people ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative ... software-as-a-service solution for increasing patient engagement and optimizing care journey management for home ...
(Date:2/20/2017)... ... , ... Clearwave is the leading provider in ... XT-series of touch screen terminals. Both companies will be showcasing their solutions at ... provider Posiflex is helping to bridge the gap between healthcare hardware and software ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... regulated industries, announced Biscom Document Router (BDR), the first IoT device from Biscom ... diagnostics and imaging. Biscom will debut BDR at HIMSS17 and will ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Devices - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:2/21/2017)... Research and Markets has announced the addition of the ... their offering. ... research Uterine cancer Drugs Price Analysis and Strategies - 2016, provides drug ... The research answers the following questions: What are ... are they positioned in the Global Uterine cancer market? ...
(Date:2/20/2017)... Feb. 20, 2017   MedPlast, Inc. , ... industry, announced today that it has signed a ... Device Manufacturing Services business.   The acquisition broadens MedPlast,s ... a leading services provider to the world,s largest ... further expand the company,s capabilities in assembly and ...
Breaking Medicine Technology: